Janumet Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss
Conditions:   Polycystic Ovary Syndrome;   Body Weight Interventions:   Drug: sitagliptin and metformin;   Drug: Metformin Sponsor:   University Medical Centre Ljubljana Completed - verified October 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2016 Category: Research Source Type: clinical trials

Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
KENILWORTH, N.J., and NEW YORK, N.Y., September 15, 2016 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 15, 2016 Category: Pharmaceuticals Source Type: clinical trials